Roivant Analyst Price Targets Rise to $46 (Guggenheim) and $55 (Piper Sandler) After Tuesday's Pulmovant PHocus Phase 2 Win; Peak Sales Estimated at ~$3 Billion in PH-ILD
Sell-side analysts moved fast Wednesday September 9, 2026 following Tuesday's positive Phase 2 PHocus readout from Roivant Sciences (NASDAQ: ROIV) subsidiary Pulmovant. Guggenheim raised its ROIV price target to $46 from $42 while maintaining a Buy rating, and Guggenheim estimated peak sales of approximately $3 billion in pulmonary hypertension associated with interstitial lung disease. Piper Sandler analyst Yasmeen Rahimi raised her price target to $55 from $40 with an Overweight rating. Roivant shares closed up approximately 17% Tuesday on the ERS Congress presentation of a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 (p<0.0001), plus placebo-adjusted improvements of +35.2 meters six-minute walk distance and −357.7 pg/mL NT-proBNP (−53.2% from baseline). The Phase 3 PHrontier study in approximately 375 patients is enrolling. If PHrontier confirms the Phase 2 signal, mosliciguat would land in a PH-ILD market currently anchored by United Therapeutics' Tyvaso (treprostinil) — the only FDA-approved therapy specifically for PH-ILD — with orally-administered Merck Winrevair (sotatercept) as a pulmonary arterial hypertension option positioned differently.